
The ADAPT study compared MiniMed 780 G against multiple daily injections of insulin with an intermittently scanned CGM. ADAPT, which included 82 subjects, marks the first multi-national, randomized controlled study comparing these methods. The study evaluated adults (18 years of age and older) not meeting glycemic targets.
Six-month data published last year demonstrated a 27.6% absolute increase in time in range and a 1.4% reduction in HbA1C for MiniMed 780G users. The data also demonstrated an overnight time in range increase of 30.2%. At the close of the six-month period, all participants in the multiple daily injection/CGM group crossed over to MiniMed 780G.
Medtronic said today that crossover study subjects reproduced these improvements, and those in the original MiniMed group sustained them at one year. The company presented results at the 2023 Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Berlin.
Get the full story at our sister site, Drug Delivery Business News.